Novel, broad-spectrum anticonvulsants containing a sulfamide group: Advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7528-7536

  Parker, Michael H ^a   Smith Swintosky, Virginia L ^a   McComsey, David F ^a   Huang, Yifang ^a   Brenneman, Douglas ^a   Klein, Brian ^a   Malatynska, Ewa ^a   White, H Steve ^c   Milewski, Michael E ^a   Herb, Mark ^a   Finley, Michael F A ^a   Liu, Yi ^a   Lubin, Mary Lou ^a   Qin, Ning ^a   Iannucci, Robert ^a   Leclercq, Laurent ^b   Cuyckens, Filip ^b   Reitz, Allen B ^a   Maryanoff, Bruce E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

( 5 FLUOROBENZO[B]THIEN 3 YL)METHYLAMINE; ANTICONVULSIVE AGENT; BENZYL DERIVATIVE; BICUCULLINE; CALCIUM CHANNEL N TYPE; CARBAMAZEPINE; CARBONATE DEHYDRATASE II; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; JNJ 26990990; LAMOTRIGINE; N ((BENZO[B]THIEN 3 YL)METHYL)SULFAMIDE; N (BENZO[B]THIEN 3 YL)ETHYL]SULFAMIDE; N [( 5 FLUOROBENZO[B]THIEN 3 YL)METHYL]SULFAMIDE; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; POTASSIUM CHANNEL; RWJ 37082; RWJ 37947; SULFAMIDE DERIVATIVE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CLINICAL STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; ELECTRIC CURRENT; EPILEPSY; FEMALE; HUMAN; HUMAN CELL; IC 50; LIVER CELL; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUROTOXICITY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; RODENT; SEIZURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMIDES; ANIMALS; ANTICONVULSANTS; CARBONIC ANHYDRASE II; CELL LINE; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MICE; RATS; SULFONAMIDES; THIOPHENES;

EID: 72249089530     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801432r     Document Type: Article

References (68)

1. (a) Maryanoff, B. E.; Nortey, S. O.; Gardocki, J. F.; Shank, R. P.; Dodgson, S. P. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis- O-(1-methylethylidene)-β-D-fructopyranose sulfamate and related compounds. J. Med. Chem. 1987, 30, 880-887.
2. (b) Shank, R. P.; Gardocki, J. F.; Vaught, J. L.; Davis, C. B.; Schupsky, J. J.; Raffa, R. B.; Dodgson, S. J.; Nortey, S. O.; Maryanoff, B. E. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994, 35, 450-460.
3. (c) Maryanoff, B. E.; Margul, B. L. Topiramate. Drugs Future 1989, 14, 342-344.
4. TOPAMAX (topiramate) had sales of approximately $2 billion/ year in 2006, as indicated in the 2006 Johnson & Johnson Annual Report (http://www.jnj.com/news/jnj-news/pdf/kp0604q9l4c3e2. pdf; accessed in Aug 2007).
5. (a) This information is based on various published reports and should not be construed as an attempt to promote the product for these therapeutic uses.
6. (b) van Passel, L.; Arif, H.; Hirsch, L. J. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev. Neurother. 2006, 6, 19-31.
7. (c) Tucker, P.; Trautman, R. P.;Wyatt, D. B.; Thompson, J.;Wu, S.-C.; Capece, J. A.; Rosenthal, N. R. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68, 201-206.
8. (a) Waugh, J.; Goa, K. L. Topiramate as monotherapy in newly diagnosed epilepsy. CNS Drugs 2003, 17, 985-992. (Pubitemid 37410073)
9. (b) White, H. S. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005, 45 (Suppl. 1), S48-S56.
10. (c) Enhancement of the inhibitory effects of γ-aminobutyric acid (GABA): Herrero, A. I.; Del Olmo, N.; Gonzalez-Escalada, J. R.; Solis, J. M. Two new actions of topiramate: inhibition of depolarizing GABA-Amediated responses and activation of a potassium conductance. Neuropharmacology 2002, 42, 210-220.
11. (d) Blockade of excitatory effect of glutamate via non-N-methyl-D- aspartate (non-NMDA) receptors: Skradski, S.; White, H. S. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000, 41 (Suppl. 1), S45-S47.
12. (e) State-dependent sodium channel blockade: McLean, M. J.; Bukhari, A. A.;Wamil, A.W. Effects of topiramate on sodium-dependent actionpotential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000, 41 (Suppl. 1), S21-S24.
13. (f) Reduction of calcium channel activity: Zhang, X.-L.; Velumian, A. A.; Jones, O. T.; Carlen, P. L. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000, 41 (Suppl. 1), S52-S60.
14. (g) Shank, R. P.; Maryanoff, B. E. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci. Ther. 2008, 14, 120-142.
15. (a) Banks, J. W. Preventive therapies for migraine headache. Pharm. Ther. 2004, 29, 784-791(http://www.ptcommunity.com/ ptjournal/fulltext/29/12/ PTJ2912784.pdf; accessed March 2007) .
16. (b) Thienel, U.; Neto, W.; Schwabe, S. K.; Vijapurkar, U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol. Scand. 2004, 110, 221-231.
17. (c) White, H. S. Mechanism of action of newer anticonvulsants. J. Clin. Psychiatry 2003, 64 (Suppl. 8), 5-8.
18. Maryanoff, B. E.; Costanzo, M. J.; Nortey, S. O.; Greco, M. N.; Shank, R. P.; Schupsky, J. J.; Ortegon, M. E.; Vaught, J. L. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J. Med. Chem. 1998, 41, 1315-1343.
19. (a) Richard, D.; Ferland, J.; Lalonde, J.; Samson, P.; Deshaies, Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000, 16, 961-966. (Pubitemid 30779800)
20. (b) York, D. A.; Singer, L.; Thomas, S.; Bray, G. A. The effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000, 16, 967-975.
21. (c) Plata-Salaman, C. R. Ingestive behavior and obesity. Nutrition 2000, 16, 797-799.
22. (d) Picard, F.; Deshaies, Y.; Lalonde, J.; Samson, P.; Richard, D. Topiramate reduces energy and fat gains in lean (fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 2000, 8, 656-663.
23. (e) Chengappa, K. N. R.; Chalasani, L.; Brar, J. S.; Parepally, H.; Houck, P.; Levine, J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an openlabel, nonrandomized chart review. Clin. Ther. 2002, 24, 1576-1584.
24. (f) Richard, D.; Picard, F.; Lemieux, C.; Lalonde, J.; Samson, P.; Deshaies, Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. 2002, 26, 344-353.
25. (g) Ben-Menachem, E.; Axelsen, M.; Johanson, E. H.; Stagge, A.; Smith, U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes. Res. 2003, 11, 556-562.
26. (h) Bray, G. A.; Hollander, P.; Klein, S.; Kushner, R.; Levy, B.; Fitchet, M.; Perry, B. H. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 2003, 11, 722-733.
27. (i) Liang, Y.; Chen, X.; Osborne, M.; DeCarlo, S. O.; Jetton, T. L.; Demarest, K. Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes, Obes. Metab. 2005, 7, 360-369. (Pubitemid 40916578)
28. (j) Wilkes, J. J.; Nelson, E.; Osborne, M.; Demarest, K. T.; Olefsky, J. M. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am. J. Physiol. 2005, 288 (3, Part 1), E617-E624.
29. (k) Liang, Y.; She, P.; Wang, X.; Demarest, K. The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metab., Clin. Exp. 2006, 55, 1411-1419.
30. (l) Eliasson, B.; Gudbjornsdottir, S.; Cederholm, J.; Liang, Y.; Vercruysse, F.; Smith, U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int. J. Obes. 2007, 31, 1140-1147.
31. (a)Maryanoff, B. E.;McComsey,D. F.;Costanzo,M. J.;Hochman, C.; Smith-Swintosky, V.; Shank, R. P. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J. Med. Chem. 2005, 48, 1941-1947.
32. (b) Klinger,A. L.; McComsey, D. F.; Smith-Swintosky, V.; Shank, R. P.; Maryanoff, B. E. Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J. Med. Chem. 2006, 49, 3496-3500.
33. (c) Shank, R. P.; McComsey, D. F.; Smith-Swintosky, V. L.; Maryanoff, B. E. Examination of two independent kinetic assays for determining the inhibition of carbonic anhydrases I and II: structureactivity comparison of sulfamates and sulfamides. Chem. Biol. Drug Des. 2006, 68, 113-119.
34. (d) Shank, R. P.; Smith-Swintosky, V. L.; Maryanoff, B. E. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J. Enzyme Inhib. Med. Chem. 2008, 23, 271-276.
35. (e) Maryanoff, B. E.; McComsey, D. F.; Lee, J.; Smith-Swintosky,V. L.; Wang, Y.; Minor, L. K.; Todd, M. J. Carbonic anhydrase-II inhibition. What are the true enzyme inhibitory properties of the sulfamide cognate of topiramate?. J. Med. Chem. 2008, 51, 2518-2521.
36. (a) Gavernet, L.; Cabrera,M. J. D.; Bruno-Blanch, L. E.; Estiu, G. L. 3D-QSAR design of novel antiepileptic sulfamides. Bioorg. Med. Chem. 2007, 15, 1556-1567.
37. (b) Gavernet, L.; Barrios, I. A.; Cravero, M. S.; Bruno-Blanch, L. E. Design, synthesis, and anticonvulsant activity of some sulfamides. Bioorg. Med. Chem. 2007, 15, 5604-5614.
38. For a review on biologically active sulfamides, see the following: Winum, J.-V.; Scozzafava, A.; Montero, J.-L.; Supuran, C. T. The sulfamide motif in the design of enzyme inhibitors. Expert Opin. Ther. Pat. 2006, 16, 27-47.
39. Swinyard, E. A.; Brown, W. C.; Goodman, L. S. Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther. 1952, 106, 319-330.
40. Swinyard, E. A. Laboratory evaluation of antiepileptic drugs: review of laboratory methods. Epilepsia 1969, 10, 107-119.
41. Cerep (Seattle, WA), an independent contract laboratory, can be contacted at www.cerep.com.
42. Shingles, R.; Moroney, J. V. Measurement of carbonic anhydrase activity using a sensitive fluorometric assay. Anal. Biochem. 1997, 252, 190-197.
43. The IC50 value for acetazolamide, a reference standard, was <10 nM.
44. A more detailed discussion of these biological studies with 4a will be published separately.
45. White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. General Principles: Discovery and Preclinical Development of Antiepileptic Drugs. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perruca, E., Eds.; Lippincott, Williams and Wilkins: Philadelphia, PA, 2002; pp 36-48.
46. Lothman, E.W.; Salerno,R.A.; Perlin, J. B.; Kaiser,D. L. Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats. EpilepsyRes. 1988, 2, 367-379.
47. Lothman, E.W.; Perlin, J. B.; Salerno, R. A. Response properties of rapidly recurring hippocampal seizures in rats. Epilepsy Res. 1988, 2, 356-366.
48. (a) Soderpalm, B. Anticonvulsants: aspects of their mechanisms of action. Eur. J. Pain 2002, 6, 3-9.
49. (b) Liu, G.; Yarov-Yarovoy, V.; Nobbs, M.; Clare, J. J.; Scheuer, T.; Catterall, W. A. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 2003, 44, 413-422.
50. (c) White, H. S.; Smith, M. D.; Wilcox, K. S. Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol. 2007, 81, 85-110.
51. (d) Rogawski, M. A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006, 69, 273-294. (Pubitemid 44209049)
52. Lombardo, A. J.; Kuzniecky, R.; Powers, R. E.; Brown, G. B. Altered brain sodium channel transcript in human epilepsy. Mol. Brain Res. 1996, 35, 84-90.
53. Rogawski, M. A.; Loscher, W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 2004, 10, 685-692.
54. Rogawski, M. A.; Loscher, W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 2004, 5, 553-564.
55. Wang, H.-S.; Pan, Z.; Shi, W.; Brown, B. S.; Wymore, R. S.; Cohen, I. S.; Dixon, J. E.; McKinnon, D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998, 282, 1890-1893.
56. Gribkoff, V. K. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin. Ther. Targets 2003, 7, 737-748.
57. Details on the metabolism and pharmacokinetics of 4a and the synthesis of 14C-labeled 4a will be published separately.
58. White, H. S.; Wolf, H. H.; Woodhead, J. H.; Kupferberg, H. J. The national institutes of health anticonvulsant drug development program: screening for efficacy. Adv. Neurol. 1998, 76, 29-39.
59. Orloff, M. J.; Williams, H. L.; Pfeiffer, C. C. Timed intravenous infusion of metrazol and strychnine for testing anticonvulsant drugs. Proc. Soc. Exp. Biol. Med. 1949, 70, 254-257.
60. White, H. S.; Patel, S.; Meldrum, B. S. Anticonvulsant profile of MDL 27,266: an orally active, broad-spectrum anticonvulsant agent. Epilepsy Res. 1992, 12, 217-226.
61. Lothman, E. W.; Salerno, R. A.; Perlin, J. B.; Kaiser, D. L. Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats. Epilepsia 1988, 2, 367-379.
62. (a) Kohling, R. Voltage-gated sodium channels in epilepsy. Epilepsia 2002, 43, 1278-1295.
63. (b) Liu, Y.; Qin, N.; Reitz, T.; Wang, Y.; Flores, C. M. Inhibition of the rat brain sodium channel Nav1.2 after prolonged exposure to gabapentin. Epilepsy Res. 2006, 70, 263-268.
64. (c) Benjamin, E. R.; Pruthi, F.; Olanrewaju, S.; Ilyin, V. I.; Crumley, G.; Kutlina, E.; Valenzano, K. J.; Woodward, R. M. State-dependent compound inhibition of Nav1.2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J. Biomol. Screening 2006, 11, 29-39.
65. Lukyanetz, E. A.; Shkryl, V. M.; Kostyuk, P. G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43, 9-18. (Pubitemid 34215447)
66. Kuzmiski, J. B.; Barr, W.; Zamponi, G. W.; Mac Vicar, B. A. Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. Epilepsia 2005, 46, 481-489.
67. (a) Dunham, M. S.; Miya, T. A. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc., Sci. Ed. 1957, 46, 208-209.
68. (b) Studies were conducted by NeuroAdjuvants under contract.